EDIT — Editas Medicine Share News
0.000.00%
Last trade - 00:00- $382.41m
- $226.51m
- $40.52m
Editas Medicine Inc expected to post a loss of 57 cents a share - Earnings Preview
Editas Medicine rises as Citi upgrades to 'buy'
U.S. STOCKS ON THE MOVE-Albemarle, Novavax, WeWork
Brief: Editas Medicine Granted FDA Regenerative Medicine Advanced Therapy Designation For EDIT-301 For The Treatment Of Severe Sickle Cell Disease
Editas climbs on FDA's 'RMAT' tag for blood disorder treatment
U.S. STOCKS ON THE MOVE-Mercato, Baytex, Ball Corp
U.S. STOCKS ON THE MOVE-SeaStar, Sigma Lithium, Brinker
U.S. STOCKS ON THE MOVE-OPKO Health, Structure Therapeutics, Blue Apron
Editas up as Stifel upgrades to 'buy' on sickle cell therapy progress
Brief: Medicenna Announces The Appointment Of Jeff Caravella As Chief Financial Officer
Editas Medicine Inc reports results for the quarter ended in June - Earnings Summary
Editas Medicine Inc expected to post a loss of 76 cents a share - Earnings Preview
Brief: Editas Medicine And Azzur Group Expand Partnership To Accelerate Editas' Manufacturing Capabilities For Advancing The Edit-301 Program Through Approval To Commercialization
U.S. STOCKS ON THE MOVE-Adobe, Nikola, copper miners
U.S. STOCKS ON THE MOVE-Premier, Canadian Solar, Jabil
U.S. STOCKS ON THE MOVE-Premier, Canadian Solar, Jabil
U.S. STOCKS ON THE MOVE-Kohl's, JinkoSolar, Kroger
U.S. STOCKS ON THE MOVE-Domino's, Aldeyra, MicroVision
Refinitiv Newscasts - U.S. Morning Call: Investors on guard for market stress as Fed signals more hikes ahead